ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Shares Bought by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP raised its holdings in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 28.8% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,086,840 shares of the biopharmaceutical company’s stock after acquiring an additional 243,082 shares during the quarter. Dimensional Fund Advisors LP’s holdings in ACADIA Pharmaceuticals were worth $19,932,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. R Squared Ltd acquired a new position in ACADIA Pharmaceuticals in the fourth quarter valued at approximately $47,000. KBC Group NV grew its position in shares of ACADIA Pharmaceuticals by 67.0% in the 4th quarter. KBC Group NV now owns 5,093 shares of the biopharmaceutical company’s stock valued at $93,000 after buying an additional 2,044 shares during the last quarter. Globeflex Capital L P purchased a new position in shares of ACADIA Pharmaceuticals in the 4th quarter valued at $168,000. Xponance Inc. acquired a new stake in ACADIA Pharmaceuticals during the 4th quarter worth $186,000. Finally, Vinva Investment Management Ltd purchased a new stake in ACADIA Pharmaceuticals in the fourth quarter valued at $187,000. Hedge funds and other institutional investors own 96.71% of the company’s stock.

ACADIA Pharmaceuticals Trading Up 1.7 %

Shares of ACAD opened at $14.79 on Thursday. The stock’s 50 day moving average is $15.87 and its two-hundred day moving average is $16.91. ACADIA Pharmaceuticals Inc. has a twelve month low of $13.40 and a twelve month high of $20.68. The firm has a market capitalization of $2.47 billion, a PE ratio of 18.96 and a beta of 0.47.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last announced its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported $0.11 earnings per share for the quarter, topping analysts’ consensus estimates of $0.10 by $0.01. ACADIA Pharmaceuticals had a return on equity of 25.83% and a net margin of 13.83%. The firm had revenue of $244.32 million for the quarter, compared to analyst estimates of $239.32 million. During the same quarter in the prior year, the company posted $0.10 earnings per share. ACADIA Pharmaceuticals’s quarterly revenue was up 18.7% on a year-over-year basis. On average, sell-side analysts predict that ACADIA Pharmaceuticals Inc. will post 0.7 EPS for the current year.

Analyst Ratings Changes

ACAD has been the topic of a number of research analyst reports. HC Wainwright reiterated a “buy” rating and set a $27.00 target price on shares of ACADIA Pharmaceuticals in a research report on Thursday, February 27th. StockNews.com upgraded ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, March 8th. UBS Group lowered their target price on shares of ACADIA Pharmaceuticals from $25.00 to $22.00 and set a “buy” rating on the stock in a research report on Monday, April 28th. Cantor Fitzgerald reiterated an “overweight” rating and set a $28.00 price target on shares of ACADIA Pharmaceuticals in a research note on Thursday, February 27th. Finally, Deutsche Bank Aktiengesellschaft started coverage on shares of ACADIA Pharmaceuticals in a research report on Tuesday, February 11th. They set a “hold” rating and a $22.00 price objective on the stock. Seven research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.com, ACADIA Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $24.21.

Insider Activity

In related news, Director Elizabeth A. Garofalo sold 4,919 shares of the firm’s stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $18.23, for a total value of $89,673.37. Following the completion of the transaction, the director now directly owns 17,595 shares of the company’s stock, valued at $320,756.85. This trade represents a 21.85 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Mark C. Schneyer sold 2,708 shares of the business’s stock in a transaction on Tuesday, April 8th. The stock was sold at an average price of $14.82, for a total value of $40,132.56. Following the sale, the executive vice president now owns 59,456 shares in the company, valued at approximately $881,137.92. The trade was a 4.36 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 18,994 shares of company stock worth $313,131 in the last 90 days. 26.50% of the stock is currently owned by corporate insiders.

ACADIA Pharmaceuticals Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.